For Investors
Prevent avoidable losses in healthcare investments — before capital is deployed.
I evaluate whether a healthcare startup will survive clinical workflows, regulatory pathways, and real-world deployment — not just pitch-stage validation.
Identified a high-risk healthcare venture after initial capital commitment — leading to withdrawal of further investment exposure. The venture remains commercially unviable.
01 — Where most healthcare investments fail
Losses don’t occur at the pitch stage — they occur during execution, when clinical, regulatory, and operational realities surface.
The idea is rarely the problem. The failure happens in translation — from concept to clinical adoption.
- Technically impressive solutions that fail inside real hospital workflows
- AI systems that look strong in demos but fail clinical usability and safety integration
- Regulatory classification errors identified only after significant capital deployment
- Premature scaling before clinical validation or hospital adoption proof
- Lack of clarity on device classification (Class I–IV) and its impact on timelines
02 — Why this filter exists
This is not generic advisory. It is Clinical Due Diligence for healthcare capital — designed to identify what will actually survive inside hospital systems.
What this filter actually detects
- Survival in real hospital workflows (ICU, OT, ward) vs. demo environments
- Adoption probability vs. remaining stuck at the pilot stage
- Accuracy of regulatory classification and its impact on cost/scale
Built from clinical + operational reality
As a practising ENT & Head-Neck Surgeon and startup founder, I have built and evaluated healthcare solutions inside real hospital environments. This creates visibility into system-level adoption failures that most investors never see.
03 — Investment filtering system
Every healthcare startup is evaluated through a structured clinical filter focused on survival under execution pressure.
- Clinical pre-screening — eliminates non-viable models early
- Hospital workflow validation — tests integration against actual environments
- Regulatory risk mapping — identifies compliance gaps and device issues
- Execution due diligence — evaluates real-world scalability potential
04 — What clinical due diligence delivers
This is decision intelligence. The outcome is fewer wrong investments, better capital timing, and reduced exposure to avoidable failure.
- A clinically validated investment pipeline
- Early identification of hidden clinical or regulatory risks
- Clear assessment of hospital adoption probability
- Clarity on capital timing — when to invest and when to walk away
05 — What separates scalable healthcare ventures
Failure occurs when clinical, regulatory, and hospital realities are not factored into investment decisions early enough.
- Clear integration into real hospital workflows
- Correct regulatory pathway from early stage
- Validated clinical need — not assumed demand
This is why Clinical Due Diligence is designed for family offices and funds where decisions require more than financial analysis alone.
Capital should enter healthcare only after clinical validation.
Available for select healthcare investment mandates.